| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $0 | 12 | 100 |
| Coll Crespo Blas | CHIEF MEDICAL OFFICER | 0 | $0 | 1 | $0 | $0 |
| FMR LLC | See Remark 1 | 0 | $0 | 6 | $0 | $0 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 5 | $0 | $0 |
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 …
Over the last 12 months, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of Structure Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-09-21 | Sale | Coll Crespo Blas | CHIEF MEDICAL OFFICER | 4,008 – | $0 | $0 | -37.84% | |
| 2026-09-01 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 5,939 – | $0 | $0 | -41.37% | |
| 2026-08-18 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 3,939 – | $0 | $0 | -34.56% | |
| 2026-08-04 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 3,939 – | $0 | $0 | -27.51% | |
| 2026-07-22 | Sale | FMR LLC | See Remark 1 | 17,452 – | $0 | $0 | -23.31% | |
| 2026-07-14 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 7,878 – | $0 | $0 | -20.18% | |
| 2026-06-25 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 7,878 – | $0 | $0 | -1.89% | |
| 2026-04-14 | Sale | FMR LLC | See Remark 1 | 17,452 – | $0 | $0 | -19.37% | |
| 2026-01-15 | Sale | FMR LLC | See Remark 1 | 17,452 – | $0 | $0 | -43.39% | |
| 2025-12-08 | Sale | FMR LLC | See Remark 1 | 32,720 – | $0 | $0 | -29.67% | |
| 2025-12-08 | Sale | FMR LLC | See Remark 1 | 35,501 – | $0 | $0 | -29.67% | |
| 2025-12-08 | Sale | FMR LLC | See Remark 1 | 52,356 – | $0 | $0 | -29.67% | |
| 2025-07-30 | Sale | FMR LLC | See Remark 1 | 26,310 – | $0 | $0 | +146.44% | |
| 2025-02-06 | Sale | FMR LLC | See Remark 1 | 41 – | $0 | $0 | -20.92% | |
| 2024-06-10 | Sale | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | 185,000 – | $0 | $0 | -39.09% | |
| 2024-06-03 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 35,400 – | $0 | $0 | -36.86% |
| Increased Positions | 124 | +62.31% | 20M | +35.41% |
| Decreased Positions | 93 | -46.73% | 11M | -19.72% |
| New Positions | 71 | New | 6M | New |
| Sold Out Positions | 29 | Sold Out | 4M | Sold Out |
| Total Postitions | 230 | +15.58% | 66M | +15.69% |
| Wellington Management Group Llp | $387,547.00 | 2.75% | 5.69M | -1M | -17.26% | 2025-09-30 |
| Fmr Llc | $357,655.00 | 2.54% | 5.25M | +335,403 | +6.82% | 2025-09-30 |
| Avoro Capital Advisors Llc | $351,196.00 | 2.49% | 5.16M | +5M | New | 2025-09-30 |
| Janus Henderson Group Plc | $303,054.00 | 2.15% | 4.45M | -124,180 | -2.72% | 2025-09-30 |
| Deep Track Capital, Lp | $287,181.00 | 2.04% | 4.22M | -918,106 | -17.88% | 2025-09-30 |
| Bvf Inc/Il | $218,251.00 | 1.55% | 3.2M | +1M | +80.87% | 2025-09-30 |
| Baker Bros. Advisors Lp | $106,002.00 | 0.75% | 1.56M | -952,658 | -37.97% | 2025-09-30 |
| Casdin Capital, Llc | $105,927.00 | 0.75% | 1.55M | +330,000 | +26.94% | 2025-09-30 |
| Ra Capital Management, L.P. | $103,367.00 | 0.73% | 1.52M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $86,822.00 | 0.62% | 1.27M | +54,496 | +4.47% | 2025-09-30 |